Skip to content

Zymeworks ZYME EBITDA margin

EBITDA margin at other companies

Pfizer logo
PfizerPFE
25.3%
Amgen logo
AmgenAMGN
41.5%+3.4pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
17.8%+9.7pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-543.2%-271pp
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-237.8%-104pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-572.1%-593pp

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

Based on trailing twelve months.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's EBITDA margin?
Zymeworks (ZYME) reported EBITDA margin of -132.6% in Q1 2026.
How has Zymeworks's EBITDA margin changed year-over-year?
Zymeworks's EBITDA margin decreased by 7.3% year-over-year, from -123.6% to -132.6%.
What is the long-term trend for Zymeworks's EBITDA margin?
Over 4 years (2020 to 2025), Zymeworks's EBITDA margin has grown at a -35.5% compound annual growth rate (CAGR), from -462% to -80%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.